Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087423 · ClinicalTrials.gov registry record · Phase 2
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 446
- Enrollment target
NCT02087423 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 446 participants.
The verdict
NCT02087423, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 446 participants
- Enrollment target
Study Summary
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
Interventions
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2014-02-25 |
| Est. Completion | 2025-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02087423
The ClinicalTrials.gov registry entry for NCT02087423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI4736 is the first listed.
NCT02087423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02087423 about?
NCT02087423 is a clinical study titled "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer". A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
What is the current status of trial NCT02087423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 446 participants. The study started on 2014-02-25. Estimated completion is 2025-03-26.
What interventions are being tested in trial NCT02087423?
The interventions under investigation include: MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02087423?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.